Search Bar & Filters
Found 6 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the effectiveness of dotinurad compared with allopurinol in lowering serum uric acid levels in adults with gout-related hyperuricemia. This Phase 3 randomized study focuses on measuring the proportion of participants achieving target serum uric acid levels at Week 24. It aims to provide insights into treatment options for people living with gout. Participants will be randomly assigned to one of three groups one group will continue allopurinol at their current stable dose once daily through Week 64, while the other two groups will receive dotinurad with dose escalation over time. Dotinurad dosing starts at 1 mg daily for the first 4 weeks, increasing to 2 mg daily through Week 64 for one group, and for the other group, it increases from 1 mg daily for 4 weeks to 2 mg daily for 8 weeks, then 4 mg daily through Week 64. Throughout the study, participants will undergo regular assessments including serum uric acid level measurements and gout flare monitoring from baseline through Week 68. Safety will also be tracked by recording adverse events. The main outcome is the percentage of participants with serum uric acid below 6.0 mgdL at Week 24. The total study duration per participant extends up to approximately 68 weeks, with ongoing evaluations to assess gout flare frequency and other relevant outcomes.
Actively Recruiting
Researchers are studying the effectiveness of dotinurad compared to allopurinol in lowering serum uric acid levels in adults with tophaceous gout. This Phase 3, randomized, double-blind trial focuses on adults aged 18 to 75 years diagnosed with gout for at least one year who have measurable tophi. The study aims to evaluate how well dotinurad lowers uric acid at Week 24 compared to allopurinol. Participants are divided into two groups. One group stops their current allopurinol and takes study-provided allopurinol once daily up to Week 76. The other group stops their prior allopurinol and starts dotinurad, beginning with 1 mg daily for the first 4 weeks, increasing to 2 mg daily for 8 weeks, then 4 mg daily through Week 76. Both treatments involve oral capsules taken once a day. This approach allows comparison of the two drugs effects over an extended treatment period. During the study, participants will have regular assessments to monitor serum uric acid levels, tophi response, and gout flare frequency up to Week 80. Safety is tracked by recording any adverse events. Data collected will include changes in uric acid, tophi area, and flare rates. Participants remain in the study for over a year, with frequent visits for evaluations and treatment adherence checks.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of cebranopadol in treating moderate to severe acute pain of surgical or non-surgical origin. This phase 3, open-label, single-arm study focuses on participants aged 18 to 75 years who experience acute pain from ambulatory surgery expected to last at least 72 hours or from traumatic or non-traumatic musculoskeletal conditions. Participants receive cebranopadol at a starting dose of 400 micrograms once daily for up to 14 days or until their pain resolves, whichever comes first. This study does not use a placebo or comparison group, and the treatment is administered openly without masking. During the study, participants will be monitored for pain intensity using the Sum of Pain Intensity Differences through 48 hours SPID48 as the primary outcome measure. They will also be evaluated for safety and tolerability over the treatment period. The study spans from September 2026 to February 2027, with ongoing assessments throughout the treatment duration.
Actively Recruiting
This trial investigates the use of genex with gentamicin genex G, an antibiotic-loaded bone void filler, as part of the surgical treatment for osteomyelitis in the extremities. It is a multi-center, single-arm pivotal device study focusing on patients diagnosed with osteomyelitis classified by the Cierny-Mader system grades I-IV. The goal is to evaluate the safety and effectiveness of genex G in supporting bone healing and treating the infection. Participants will undergo surgical debridement followed by implantation of genex with gentamicin into the bone void as part of their treatment. They will also receive antibiotics according to clinical needs determined by their treatment site. The study involves a single treatment group where all participants receive genex G during surgery, and they will be monitored for 24 months after treatment to assess outcomes. During the study, participants will have regular follow-up visits to monitor infection resolution, bone healing, and any adverse events. Assessments include clinical evaluations, radiographic imaging, and quality of life questionnaires over a 24-month period. Researchers will measure the need for additional antibiotics or surgery, recurrence of infection signs, bone healing progress, and safety related to the device. The total participation time extends up to 24 months after surgery.
Actively Recruiting
Phase IIIA Study of ELU42 Topical Spray for Treating Wagner Grade 1-2 Diabetic Foot Ulcers in Adults
Researchers are evaluating ELU42, a topical small molecule combining a tankyrase inhibitor with a special hyaluronic acid, to study its safety and early effects on chronic diabetic foot ulcers. This Phase IIIA open-label study focuses on adults with Wagner grade 1-2 diabetic foot ulcers lasting between 4 and 52 weeks. The study aims to assess how ELU42 affects wound healing and monitors safety through various health measures. Participants will first receive standard wound care for two weeks, including offloading, dressings, and cleaning. Then, ELU42 topical spray will be applied by trained staff to the ulcer three times a week for six weeks, with up to 18 treatments possible. If the wound heals but later reopens, participants may undergo another six-week treatment course. The study includes weekly visits during treatment and follow-ups for up to six weeks, with additional visits if the wound closes to observe healing over three months. During the study, participants will undergo safety evaluations such as blood tests, heart monitoring, and nutritional assessments. Researchers will measure wound healing by tracking the reduction in ulcer area at weeks 4 and 6 using both manual and automated methods. Secondary assessments include complete wound closure, wound hydration, patient-reported outcomes, and drug level monitoring in some participants. The total participation time includes treatment and follow-up periods up to several months.
Actively Recruiting
Researchers are studying Medicare beneficiaries with Lumbar Spinal Stenosis LSS and Neurogenic Claudication NC to compare outcomes after two different procedures MILD Percutaneous Image-Guided Lumbar Decompression and Interspinous Process Decompression IPD. This observational study tracks patients treated since January 1, 2017, evaluating the rates of surgical and minimally invasive interventions as well as any harms related to these procedures over 24 months. The study uses Medicare claims data and does not require prior patient consent or IRB oversight. The study includes two groups of patients those who received the MILD procedure, involving partial decompression under image guidance by removing tissue and bone at the affected spinal level, and those who underwent IPD, a device-based decompression technique. Both groups are observed through Medicare data for two years after their initial procedure to assess the need for further surgeries or interventions and to monitor for any complications. Participants are followed for 24 months after their index procedure using Medicare claims data. Researchers monitor the rates of harms associated with the initial treatment and the frequency of additional surgical or minimally invasive interventions. Since this is an observational study, data collection relies on existing Medicare records without direct patient involvement, and the study will continue enrolling patients until the sponsor stops it.